Ask AI

Lymphomas

Share

Program Content

Activities

CLL17
CLL17: Phase III Trial of Continuous Ibrutinib vs Fixed-Duration Venetoclax Plus Obinutuzumab or Venetoclax Plus Ibrutinib for Untreated CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

CaDAnCe 101
CaDAnCe-101 Update: Phase I Study Evaluating BTK Degrader BGB-16673 in R/R CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

Sonrotoclax RR MCL
Phase I/II Trial of Sonrotoclax (BGB-11417) in R/R Mantle Cell Lymphoma After Prior BTK Inhibitor Therapy 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner